ZYNE Zynerba Pharmaceuticals, Inc.

+0  (0%)
Previous Close 7.30
Open 7.30
Price To book 1.86
Market Cap 67.15M
Shares 9,199,000
Volume 112,586
Short Ratio 5.08
Av. Daily Volume 201,943

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
Phase 2 to be initiated 2H 2017.
Peripheral Neuropathic Pain (PNP)
Phase 2 trial initiation announced January 3, 2017. Data are due 3Q 2017.
Fragile X syndrome
Phase 2 initiated September 2016. Data are due July or August 2017.
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. ETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 17, 2017
  2. Yikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016
  3. Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
  4. Zynerba Pharmaceuticals, Inc. :ZYNE-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
  5. Edited Transcript of ZYNE earnings conference call or presentation 27-Mar-17 12:30pm GMT
  6. Zynerba reports 4Q loss
  7. Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights
  8. Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed
  9. Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
  10. Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
  11. Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
  12. Emerging Cannabis Industry Presents Big Opportunities For Investors
  13. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  14. Zynerba Pharmaceuticals (ZYNE) Shares March Higher, Can It Continue?
  15. Patterson Companies (PDCO) Q3 Earnings: What's in Store?
  16. Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
  17. Harry Boxer: These four momentum stocks are breaking out
  18. Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
  19. Innovative Marijuana-Based Medicines In the Making